106 results about "Rifaximin" patented technology

Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ have been discovered. These forms are useful in the production of medicinal preparations for oral and topical use and can be obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by the addition of water at a determinate temperature and for a determinate period of time. The crystallization is followed by drying carried out under controlled conditions until a specific water content is reached in the end product.

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

A stable amorphous form of rifaximin is disclosed. This form is chemically and polymorphically stable on storage and can be prepared by dissolving rifaximin in a solvent to form a solution, which is precipitated by adding an anti-solvent and isolating of the precipitated amorphous rifaximin as an end product.

Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ have been discovered. These forms are useful in the production of medicinal preparations for oral and topical use and can be obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by the addition of water at a determinate temperature and for a determinate period of time. The crystallization is followed by drying carried out under controlled conditions until a specific water content is reached in the end product.

Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

An oral preparation consisting of a non-systemic antibiotic and a proton pump blocker used for prevention of aspiration pneumonia and sepsis; and a method of prevention of aspiration pneumonia and / or sepsis by orally administering to a subject in need of such treatment a composition containing a therapeutically effective amount of rifaximin.

Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.

Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.

The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.

Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.

The invention belongs to the field of veterinary medicine, and particularly relates to a rifaximin vaginal suppository for livestock and a preparation method for the same. The suppository contains the following components: 8.5-25.5 parts by weight of rifaximin solid dispersion, 30-88 parts by weight of matrix, 6.0-12.5 parts by weight of water, 0.01-1.0 parts by weight of surfactant, 0.01-10.0 parts by weight of synergist and 0.01-5.0 parts by weight of preservative, wherein the rifaximin solid dispersion is obtained by melting 7.3-21.9 parts by weight of solid dispersion carrier in a water bath at 70-80 DEG C, and then adding the used 2-16 parts by weight of absolute ethyl alcohol to dissolve 1.2-3.6 parts by weight of rifaximin to obtain rifaximin solution, uniformly stirring, steaming away the absolute ethyl alcohol in the water bath at 70-80 DEG C, and then rapidly cooling and solidifying. The suppository disclosed by the invention can ensure the uniform dispersion of main medicine and overcome the problems of low heat resistance and long melting time limit of glycerin gelatine matrix.

The invention discloses a rifaximin medicine composition and a preparation method of the rifaximin medicine composition. The rifaximin medicine composition comprises the following ingredients in percentages by mass: 40-60% of rifaximin, 10-50% of microcrystalline cellulose, 1-30% of sodium carboxymethyl starch or sodium carboxymethyl starch, 0.5-6% of silicon dioxide, 0.5-6% of stearic acid and a little amount of aqueous solution of hydroxy propyl cellulose with the mass concentration of 0.5-6%. The medicine composition can be made into tablets and capsules, each dose comprises 550mg of rifaximin respectively, and a coating solution for the preparation is an aqueous solution of opadry with the mass concentration of 5-30%. The invention also provides the preparation method of the rifaximin medicine composition. According to the rifaximin medicine composition and the preparation method of the rifaximin medicine composition disclosed by the invention, the preparation of the medicine composition can be rapidly disintegrated to fully take medicine efficacy, so as to improve the health of a patient suffering from liver cirrhosis recurrent hepatic encephalopathy.

The invention discloses rifaximin suspension containing montmorillonite, which belongs to the field of veterinary preparations. The rifaximin suspension comprises the following components by weight percent: 5-15% of rifaximin, 7.5-22.5% of the montmorillonite, 0.5-2% of suspending agent, 0.2-1% of surface active agent, 0.2-1% of deflocculating agent and the balance of water. The invention further discloses a preparation method of the rifaximin suspension, which comprises the following steps: adding the suspending agent, the surface active agent and the deflocculating agent into the water according to proportion, uniformly mixing and performing water bathing for 1-3 hours at the temperature of 65 DEG C; further adding the rifaximin and the montmorillonite into a stirrer for stirring; and adding the water to volume, homogenizing and sterilizing. The rifaximin in the rifaximin suspension is small in particle size, the release amount and the release speed of active ingredients are greatly improved, and the bioavailability of the rifaximin is improved; secondly, the mortality rate of livestock and poultry with diseases caused by diarrhea can be reduced; in addition, the rifaximin suspension is good in stability and suitable for long-term preservation.

Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

The invention belongs to the field of veterinary medicine, and particularly relates to a compound rifaximin dry suspension for preventing and treating the endometritis of livestock and a preparation method for the same. The rifaximin and sodium new houttuyfonate dry suspension is obtained by using rifaximin and sodium new houttuyfonate as active ingredients, and preparing with pharmaceutically acceptable auxiliary materials. The preparation method comprises the following steps of: performing superfine crushing treatment on raw materials at first; uniformly mixing the treated rifaximin and sodium new houttuyfonate with right amount of filler, suspending aid, surfactant, lubricant, adsorbent and pH buffer according to an equivalent incremental mixing method; subpackaging and sterilizing for1 hour by flowing steam at 100 DEG C. Rifaximin is a novel rifamycin board-spectrum semisynthetic antibiotic medicine, with the advantages of board-spectrum antibacterium, antitoxin and the like, andcapable of preventing and treating the endometritis of dairy cow well; and sodium new houttuyfonate is antibacterial, anti-inflammatory and capable of enhancing immunity as well as resisting bacteriaand diminishing inflammation by cooperating with rifaximin, and has great effect of preventing and treating the endometritis of dairy cow.

A dried rifaximin suspensoid pelletized granule, which is prepared by mixing rifaximin as the active component and medicinal auxiliary materials at the weight ratio of 1í†5í½35. The medicinal auxiliary materials mainly comprise the suspending agent and the flocculating agent at the weight ratio of 1í†0.05í½2. The suspending agent comprises two or three of microcrystal cellulose, methylcellulose, sodium methylol cellulose, hydroxypropyl methylcellulose, sodium alginate, gum arabic and pectine. The flocculating agent is one of citrate, tartrate, phosphate and aluminum chloride. Other auxiliary materials contain cane sugar, starch, food sweetening agent, preservative and flavoring and so on.

The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.

The invention discloses application of a rifamycin-nitroimidazole coupling molecule represented in a formula I in inhibition of anaerobic or facultative anaerobic ammonia producing floras in gastrointestinal tracts. The rifamycin-nitroimidazole coupling molecule represented in the formula I is similar to an antibacterial spectrum of rifaximin and has relatively strong antibacterial activity to common ammonia producing floras in the gastrointestinal tracts; and meanwhile, the rifamycin-quinolizidone dual-target molecule has the property of low spontaneous drug resistance frequency and has very good application prospects in prevention and treatment of infection of hepatic encephalopathy and relevant anaerobic bacteria. The formula is as shown in the specification.

The present invention relates to a new amorphous form of rifaximin and to methods for the preparation thereof by means of high energy milling or Spray drying. The present invention further relates to a new amorphous form for use as medicament and to the pharmaceutical compositions composing it.

The invention discloses a process for preparing rifaximin, which comprises the following steps: fortimicin O is reacted with excessive 2-amino-4-picolyl for 20-24 hours at 35-45 DEG C by using ethanol as a reaction solvent; after the reaction, anhydrous potassium carbonate is added, wherein the mole number of the added anhydrous potassium carbonate is 0.9-1.1 times of that of the fortimicin O; the obtained mixture is stirred and filtered, and deionized water is added to obtained filter liquor for crystallizing; obtained filter mass is filtered; and after the filter mass is dried, a finished rifaximin product is obtained. The invention has the advantages of short time of the preparation process, simple and convenient post treatment, environmental protection, low consumption, high yield and low cost.